1 citations
,
September 2023 in “Journal of the American Academy of Dermatology” Guselkumab significantly improves quality of life for people with moderate to severe psoriasis.
September 2024 in “Cureus” Guselkumab effectively treats skin reactions caused by adalimumab in certain conditions.
September 2023 in “Journal of the American Academy of Dermatology” Guselkumab effectively reduces fatigue in Psoriatic Arthritis patients over two years.
September 2023 in “Journal of the American Academy of Dermatology” Guselkumab significantly improves psoriasis symptoms within 12 weeks.
2 citations
,
December 2024 in “Journal of Dermatological Treatment” IL-23 inhibitors may help treat other skin conditions, but more research is needed.